After a median follow-up of 317 months ( IQR 278-361 ) , overall survival was significantly improved for patients with adenocarcinoma histology who progressed within 9 months after start of first-line treatment in the docetaxel plus nintedanib group ( 206 patients ) compared with those in the docetaxel plus placebo group ( 199 patients ; median 109 months [ 95 % CI 85-126 ] vs 79 months [ 67-91 ] ; HR 075 [ 95 % CI 060-092 ] , p = 00073 ) .